-

Agilent Expands Cross-Vendor CDS Instrument Control

New software extends the company’s compatibility strategy

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest implementation of its mutual compatibility philosophy. Now, joint customers of Agilent Technologies and Thermo Fisher Scientific can choose a chromatography data system from either company—Agilent OpenLab CDS or Thermo Fisher Chromeleon—to control analytical instruments from both organizations.

The two companies recognize that reliable multivendor instrument control is critical to the successful operation of today’s analytical laboratories. Using a single data system increases lab productivity by saving substantial time managing software, training staff, and making it easier to meet the regulations that govern the lab.

“Agilent's multivendor control approach to laboratory informatics allows our customers to select the best hardware and software for their needs,” said John Sadler, vice president and general manager of Agilent's Software and Informatics Division. “That is why we invest in integrating third-party analytical instruments into our OpenLab software suite, in collaboration with other analytical instrument manufacturers. Our goal is to provide simple and complete support for our mutual customers.”

Agilent OpenLab CDS streamlines laboratory operations with a single, secure data system that combines chromatography and mass spectrometry into one software platform. OpenLab CDS is a multivendor platform controlling Agilent GC, LC, single quadrupole GC/MS, LC/MS instruments along with many other instrument vendors.

Thermo Fisher Scientific instrument families are the latest additions to OpenLab CDS multivendor control program. OpenLab CDS tools provide time-saving steps in the analysis, interpretation, and reporting workflows, enabling users to quickly identify key information, improve turnaround time, and ensure the highest level of data integrity.

“The lack of interoperability between different vendors’ instruments and software has traditionally presented a barrier to laboratories adopting the right solutions to meet the unique needs of their workflows,” said Matt Hazlewood, senior director, global enterprise chromatography data systems, at Thermo Fisher Scientific. “The renewal of our commitment with Agilent for mutual compatibility and third-party control of instruments ensures that customers will have continued access to our market-leading Chromeleon CDS software platform, meaning they can deploy the analytical solutions they need without compromising the flexibility or efficiency of their workflows.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025. First-quarter GAAP net income was $305 million, or $1.07 per share. This compares with $318 million, or $1.11 per share, in the first quarter of 2025. Non-GAAP(2) net income was $386 million, or $1.36 per share, during the quarter, compared wi...

Agilent to Participate in TD Cowen’s 46th Annual Health Care Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Chief Financial Officer Adam Elinoff and Head of Investor Relations Tejas Savant will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference. The event is scheduled for 11:10 to 11:40 a.m. EST on Tuesday, March 3, 2026, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Tec...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharm...
Back to Newsroom